2006 Thomas Weisel
     Healthcare
    Conference

 September 8, 2006
Jeff Campbell

Executive Vice President and
   Chief Financial Officer




                               2
Safe Harbor Clause
Some of the information in this presentation may constitute
forward-looking statements that are subject...
McKesson At-a-Glance

 $88 billion in revenues in FY06
 Three segments: Pharmaceutical Solutions, Medical-
 Surgical Solut...
McKesson at the Center of
Healthcare


                                       Scanning 300 million
                       ...
Leading Market Positions in All
Three Segments
              Pharmaceutical                        Medical-Surgical       ...
Factors Driving Sustained
Value Creation at McKesson
 Well-positioned in growing healthcare services markets
 Strong and g...
Fireside Chat




                8
Upcoming SlideShare
Loading in …5
×

Thomas Weisel Partners Healthcare Conference Presentation

313 views
272 views

Published on

Published in: Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
313
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Thomas Weisel Partners Healthcare Conference Presentation

  1. 1. 2006 Thomas Weisel Healthcare Conference September 8, 2006
  2. 2. Jeff Campbell Executive Vice President and Chief Financial Officer 2
  3. 3. Safe Harbor Clause Some of the information in this presentation may constitute forward-looking statements that are subject to various uncertainties. These uncertainties could cause actual results to differ materially from those projected or implied. The risk factors associated with those uncertainties are described in the Company’s reports and exhibits filed with the Securities and Exchange Commission. Financial information is presented here in summary form. Full details are provided in the Company’s most recent 10-K report. All of this information is available at www.mckesson.com. The Company assumes no obligation to update or revise any such statements, whether as a result of new information or otherwise. 3
  4. 4. McKesson At-a-Glance $88 billion in revenues in FY06 Three segments: Pharmaceutical Solutions, Medical- Surgical Solutions, Provider Technologies FY06 EPS $2.44 (excluding Securities Litigation charge and Discontinued Operations) More than 26,000 employees 304 million shares outstanding $16 billion market cap Founded 1833, headquartered in San Francisco 4
  5. 5. McKesson at the Center of Healthcare Scanning 300 million doses per year to $1.6 billion of drugs per week – prevent 203,000 med 35% of drugs in North America errors per week Information solutions used by 3,500 hospitals, 200,000 physicians, 500,000 nurses and 600 payors Disease Diagnostic care guidelines for 3,500 management for health plans, hospitals and 1.5 million Medicaid government agencies and Medicare 99% daily fill rates to patients 25,000 pharmacies 5
  6. 6. Leading Market Positions in All Three Segments Pharmaceutical Medical-Surgical Provider Solutions Solutions Technologies #1 in U.S., Canada, and 63% of U.S. health #1 in primary care Mexico systems #1 in extended care #1 generics distributor Leader in clinical, revenue cycle, Private label Large Rx repackaging and resource product offerings management solutions Specialty distribution & Rapid growth in patient services for More “Best in KLAS” physician office manufacturers products than any pharmaceuticals other vendor #1 in medical management and equipment software and services for #1 hospital automation payors Emerging business in #1 in disease management U.K and France for Medicaid agencies $83.4 billion revenues $3.1 billion revenues $1.5 billion revenues $1.2 billion op profit $70 million op profit $143 million op profit Note: Financial information for year ending FY06 6
  7. 7. Factors Driving Sustained Value Creation at McKesson Well-positioned in growing healthcare services markets Strong and growing global businesses: Solid operating profit from core pharmaceutical distribution business Upside opportunities from higher-growth, higher-margin businesses without focused risk exposure Track record of improving financial performance producing strong balance sheet and solid cash flow enables disciplined and opportunistic portfolio approach to shareholder value creation Experienced and deep management team Sustained Value Creation 7
  8. 8. Fireside Chat 8

×